Dr. Reddy's Laboratories Ltd. (RDY)

36.56
0.48 1.30
NYSE : Health Technology
Prev Close 36.08
Open 36.40
Day Low/High 36.05 / 36.75
52 Wk Low/High 29.00 / 42.82
Volume 134.52K
Avg Volume 166.60K
Exchange NYSE
Shares Outstanding 166.01M
Market Cap 6.08B
EPS 1.60
P/E Ratio 21.98
Div & Yield 0.29 (0.74%)
Promius Pharma Launches Sernivo™ (betamethasone Dipropionate) Spray, 0.05%

Promius Pharma Launches Sernivo™ (betamethasone Dipropionate) Spray, 0.05%

Dr. Reddy's Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

The biotechnology company, which makes alcoholism drug Horizant, was acquired by privately held Arbor Pharmaceuticals for $467 million in cash, a price lower than at least one analyst expected.

Dr. Reddy's Q4 And FY16 Financial Results

Dr. Reddy's Q4 And FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces The Appointment Of Mr. Bharat Doshi As An Additional Independent Director On The Board Of The Company

Dr. Reddy's Laboratories Announces The Appointment Of Mr. Bharat Doshi As An Additional Independent Director On The Board Of The Company

Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr.

Dr. Reddy's To Release Q4 And Full Year FY16 Results On May 12, 2016; Earnings Call Slated For May 12, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q4 And Full Year FY16 Results On May 12, 2016; Earnings Call Slated For May 12, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting.

ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 Mg, Approved By The FDA In January 2016 For The Acute Treatment Of Migraine With Or Without Aura In Adults, Is Now Commercially Available In The U.S.

ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 Mg, Approved By The FDA In January 2016 For The Acute Treatment Of Migraine With Or Without Aura In Adults, Is Now Commercially Available In The U.S.

Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouch is now commercially available in the U.

Dr. Reddy's Laboratories Acquires The Rights To Investigational Anticancer Agent E7777 For U.S., Europe And Certain Emerging Markets From Eisai

Dr. Reddy's Laboratories Acquires The Rights To Investigational Anticancer Agent E7777 For U.S., Europe And Certain Emerging Markets From Eisai

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a licensing agreement with Eisai Co.

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc.

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc.

Dr. Reddy's And TR-Pharm Announce Strategic Collaboration In Turkey

Dr. Reddy's And TR-Pharm Announce Strategic Collaboration In Turkey

Dr. Reddy's and TR-Pharm announced today a strategic collaboration agreement involving 3 biosimilar products.

IMPORTANT SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

IMPORTANT SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

Scott + Scott, LLP, a global investor rights law firm, has opened an investigation to determine whether Dr.

Dr. Reddy's Laboratories Limited's ("Company") Board Approves The Proposal For Buyback Of Its Equity Shares

Dr. Reddy's Laboratories Limited's ("Company") Board Approves The Proposal For Buyback Of Its Equity Shares

The Board of Directors of the Company in their meeting held on 17 th February, 2016 has approved a proposal to buyback Equity Shares of the Company, subject to approval by the shareholders, for an aggregate amount not...

Dr. Reddy's Q3 And 9M FY16 Financial Results

Dr. Reddy's Q3 And 9M FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Promius Pharma™ Receives FDA Approval For Sernivo (betamethasone Dipropionate) Spray, 0.05%

Promius Pharma™ Receives FDA Approval For Sernivo (betamethasone Dipropionate) Spray, 0.05%

Dr. Reddy's announced today that its US subsidiary, Promius Pharma TM, LLC, U.

SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

Scott + Scott, LLP, a global investor rights law firm, has opened an investigation to determine whether Dr.

Dr. Reddy's Laboratories Receives USFDA Tentative Approval For Zenavod™ (doxycycline) Capsules, 40 Mg For The Treatment Of Rosacea In Adults

Dr. Reddy's Laboratories Receives USFDA Tentative Approval For Zenavod™ (doxycycline) Capsules, 40 Mg For The Treatment Of Rosacea In Adults

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today the U.

Dr. Reddy's Laboratories Ltd. Receives FDA Approval For ZEMBRACE™SymTouch™ (sumatriptan Succinate) Injection For The Acute Treatment Of Migraines In Adults

Dr. Reddy's Laboratories Ltd. Receives FDA Approval For ZEMBRACE™SymTouch™ (sumatriptan Succinate) Injection For The Acute Treatment Of Migraines In Adults

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the U.

Dr. Reddy's To Release Q3FY16 Results On Feb 9, 2016; Earnings Call Slated For Feb 9, 6:30 PM IST / 8:00 AM EST

Dr. Reddy's To Release Q3FY16 Results On Feb 9, 2016; Earnings Call Slated For Feb 9, 6:30 PM IST / 8:00 AM EST

Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Third Quarter and 9 months ended December 31, 2015 on Tuesday, February 9, 2016 after the Board Meeting.

Dr. Reddy's Announces The Relaunch Of Esomeprazole Magnesium Delayed-Release Capsules, USP

Dr. Reddy's Announces The Relaunch Of Esomeprazole Magnesium Delayed-Release Capsules, USP

Dr. Reddy's today announced the re-launch of its Esomeprazole Magnesium Delayed-Release Capsules, a therapeutic equivalent generic version of Nexium® (esomeprazole magnesium) Delayed-Release capsules in the US market.

Despite Legal Troubles, Is Dr. Reddy's a Buy?

Despite Legal Troubles, Is Dr. Reddy's a Buy?

Does the mess around Dr. Reddy's make it a good buying opportunity

Dr. Reddy's Issues A Clarification Note

Dr. Reddy's Issues A Clarification Note

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY): Reacting to certain statements that appeared in the media today relating to its corporate governance practices, Dr.

Dr. Reddy's Announces The Completion Of Fondaparinux Intellectual Property Purchase

Dr. Reddy's Announces The Completion Of Fondaparinux Intellectual Property Purchase

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) today announced that it has completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic...

Dr Reddy Laboratories (RDY) Showing Signs Of Perilous Reversal Today

Dr Reddy Laboratories (RDY) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a "perilous reversal" (up big yesterday but down big today) candidate

Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong on high relative volume candidate

TheStreet Quant Rating: C (Hold)